The rapid startup of carbon dioxide reduction-methanogenic microbial electrosynthesis is crucial for its industrial application, and the development of cathode biofilm is the key to its industrialization. Based on the new discovery that biofilm formed by placing graphite felt in an anaerobic reactor was electroactive, with strong direct electron transfer and methanogenesis ability (24.52 mL/L/d), a new startup method was developed. The startup time was shortened by at least 20 days and charge transfer resistance was reduced by 4.45-10.78 times than common startup methods (inoculating cathode effluent or granular sludge into the cathode chamber). The new method enriched electroactive bacteria. Methanobacterium and Methanosaeta accounted for 62.04% and 34.96%, respectively. The common methods inoculating cathode effluent or granular sludge enriched hydrogenotrophic microorganisms (>95%) or Methanosaeta (54.10%) due to the local environments of cathode. This new rapid and easy startup method may support the scale-up of microbial electrosynthesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biortech.2022.127385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Financial Barriers to Expanded Birth Center Access in New Jersey: A Qualitative Thematic Analysis.
J Midwifery Womens Health
January 2025
Rutgers University School of Nursing, New Brunswick, New Jersey.
Introduction: Birth centers are an underused care setting with potential to improve birth experience and satisfaction. Both hospital-based and freestanding birth centers operate with the midwifery model of care that focuses on safe, low-intervention physiologic birth experiences for healthy, low-risk pregnant people. However, financial barriers limit freestanding birth center sustainability and accessibility in New Jersey, especially for traditionally marginalized populations.
View Article and Find Full Text PDFThe Alzheimer’s Tau Platform (ATP): a Phase 2, combination amyloid and tau therapy clinical trial for early AD.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Background: Anti‐amyloid immunotherapies modestly slow disease progression in early symptomatic AD; addition of other therapeutic modalities may be necessary to achieve larger treatment effects. Therapies that directly target tau can potentially produce substantial clinical benefit because the accumulation of insoluble tau protein is strongly correlated with the progression of AD. Which tau therapies are likely to be efficacious, whether or not to combine them with anti‐amyloid therapies, and which individuals are most likely to benefit are important unresolved questions that would require multiple parallel design trials to answer.
View Article and Find Full Text PDFProtocol for an acceptability and feasibility study of sensor‐instrumented SmartSocks® for use by people with dementia.
Alzheimers Dement
December 2024
Milbotix Ltd, Chipping Norton, Oxfordshire, United Kingdom
Background: Currently ∼50% of people with dementia experience behavioural symptoms linked to unmanaged distress. Effective and safe management of these symptoms is critical to maintain the quality of life and overall care of people with dementia. Technological solutions have the potential to help with research into these symptoms.
View Article and Find Full Text PDFS6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance.
Int J Biol Sci
January 2025
Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Most tumors initially respond to treatment, yet refractory clones subsequently develop owing to resistance mechanisms associated with cancer cell plasticity and heterogeneity. We used a chemical biology approach to identify protein targets in cancer cells exhibiting diverse driver mutations and representing models of tumor lineage plasticity and therapy resistance. An unbiased screen of a drug library was performed against cancer cells followed by synthesis of chemical analogs of the most effective drug.
View Article and Find Full Text PDFA specific and adaptable approach to track CD206 macrophages by molecular MRI and fluorescence imaging.
Theranostics
January 2025
Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, 02129, MA.
The mannose receptor (CD206, expressed by the gene ) is a surface marker overexpressed by anti-inflammatory and pro-tumoral macrophages. As such, CD206 macrophages play key roles in the immune response to different pathophysiological conditions and represent a promising diagnostic and therapeutic target. However, methods to specifically target these cells remain challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!